A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers
A study for patients with select advanced cancers using study drug INCB24360
Sponsor: InCyte
Enrolling: Male and Female Patients
IRB Number: AAAO2406
U.S. Govt. ID: NCT02327078
Contact: Richard Carvajal MD: 646-248-1703 / rdc2150@cumc.columbia.edu
Additional Study Information: The purpose of this study is to assess how safe and well tolerated study drugs, INCB24360 and nivolumab, are given in combination in patients who have advanced or metastatic solid tumors. The study will also assess how well INCB24360 in combination with nivolumab works in preventing disease progression in patients with melanoma (MEL), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), head and neck squamous cell carcinoma (SCCHN), ovarian cancer and diffuse large B cell lymphoma.
This study is closed
Richard Carvajal, MD
Do You Qualify?
Do you have a confirmed diagnosis of NSCLC, MEL, CRC, SCCHN, or ovarian cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Richard Carvajal MD